Welcome to our dedicated page for Genmab A/S SEC filings (Ticker: GNMSF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genmab A/S filings document the disclosures of a foreign private issuer in biotechnology, with Form 6-K reports covering interim financial results, company announcements and exhibits incorporated by reference into S-8 registration statements. The filings describe antibody-medicine revenue drivers, collaboration royalties related to DARZALEX and Kesimpta, and pipeline disclosures for programs including EPKINLY, Rina-S and petosemtamab.
The company’s regulatory reports also record Danish capital-markets announcements, major shareholder notifications, share-capital reductions, voting-rights disclosures and governance-related corporate actions. These filings frame Genmab’s public-company record around operating performance, capital structure, ownership reporting, product-regulatory updates and risks tied to developing and commercializing antibody therapeutics.
Genmab A/S reports changes to its board leadership and new employee equity incentives. Following the Annual General Meeting, Deirdre P. Connelly was appointed Chair of the Board and Pernille Erenbjerg was appointed Deputy Chair.
The company decided to grant 5,213 restricted stock units and 4,485 warrants to employees of Genmab and its subsidiaries. Each restricted stock unit is awarded cost-free, has a fair value equal to the closing share price of DKK 1,645.00 at grant, and vests after three years subject to program conditions. Each warrant is also granted cost-free with an exercise price of DKK 1,645.00, has a fair value of DKK 530.62 based on the Black-Scholes formula, vests after three years, and expires seven years from the grant date.
Genmab A/S reports changes to its board leadership and new employee equity incentives. Following the Annual General Meeting, Deirdre P. Connelly was appointed Chair of the Board and Pernille Erenbjerg was appointed Deputy Chair.
The company decided to grant 5,213 restricted stock units and 4,485 warrants to employees of Genmab and its subsidiaries. Each restricted stock unit is awarded cost-free, has a fair value equal to the closing share price of DKK 1,645.00 at grant, and vests after three years subject to program conditions. Each warrant is also granted cost-free with an exercise price of DKK 1,645.00, has a fair value of DKK 530.62 based on the Black-Scholes formula, vests after three years, and expires seven years from the grant date.
Genmab A/S held its Annual General Meeting on March 19, 2026, where shareholders approved the 2025 Annual Report and gave discharge to the Board of Directors and Executive Management. The year’s profit of USD 963 million will be carried forward to retained earnings.
Six directors were re-elected for one year, and Deloitte was re-appointed as auditor. Shareholders also approved a reduction of the company’s share capital by nominally DKK 1,900,000 through cancellation of treasury shares. The proposal on 2026 Board remuneration was withdrawn, with a new proposal to be presented later.
Genmab A/S held its Annual General Meeting on March 19, 2026, where shareholders approved the 2025 Annual Report and gave discharge to the Board of Directors and Executive Management. The year’s profit of USD 963 million will be carried forward to retained earnings.
Six directors were re-elected for one year, and Deloitte was re-appointed as auditor. Shareholders also approved a reduction of the company’s share capital by nominally DKK 1,900,000 through cancellation of treasury shares. The proposal on 2026 Board remuneration was withdrawn, with a new proposal to be presented later.
Genmab A/S has completed its share buy-back program, repurchasing 342,130 shares for a total of 615,105,001 DKK to meet commitments under its Restricted Stock Unit program. The program, launched on February 17, 2026, finished on March 13, 2026, earlier than expected.
From March 9 to March 13, 2026, Genmab bought 93,130 shares, including 25,130 shares on March 13 at an average price of 1,717.39 DKK. After these transactions, Genmab holds 2,859,663 treasury shares, representing 4.45% of its total share capital and voting rights.
Genmab A/S has completed its share buy-back program, repurchasing 342,130 shares for a total of 615,105,001 DKK to meet commitments under its Restricted Stock Unit program. The program, launched on February 17, 2026, finished on March 13, 2026, earlier than expected.
From March 9 to March 13, 2026, Genmab bought 93,130 shares, including 25,130 shares on March 13 at an average price of 1,717.39 DKK. After these transactions, Genmab holds 2,859,663 treasury shares, representing 4.45% of its total share capital and voting rights.
Genmab A/S provides an update on its share buy-back program launched on February 17, 2026 to repurchase up to 342,130 shares with a maximum aggregate value of DKK 725 million to cover Restricted Stock Unit commitments. From March 2 to March 6, 2026, the company repurchased 101,000 shares for a total of DKK 180,733,150, bringing total repurchases under the program to 249,000 shares at a total value of DKK 452,588,620. Genmab corrects a previously reported “Accumulated through last announcement” figure, which should have been 63,000 shares, resulting in a corrected accumulated figure of 148,000 shares. After these transactions, Genmab holds 2,766,533 treasury shares, equal to 4.31% of its total share capital and voting rights.
Genmab A/S provides an update on its share buy-back program launched on February 17, 2026 to repurchase up to 342,130 shares with a maximum aggregate value of DKK 725 million to cover Restricted Stock Unit commitments. From March 2 to March 6, 2026, the company repurchased 101,000 shares for a total of DKK 180,733,150, bringing total repurchases under the program to 249,000 shares at a total value of DKK 452,588,620. Genmab corrects a previously reported “Accumulated through last announcement” figure, which should have been 63,000 shares, resulting in a corrected accumulated figure of 148,000 shares. After these transactions, Genmab holds 2,766,533 treasury shares, equal to 4.31% of its total share capital and voting rights.
Genmab A/S has furnished a Form 6-K for March 2026, primarily to submit its updated Articles of Association as Exhibit 3.1. The filing states that this report will be incorporated by reference into several existing Genmab Form S-8 registration statements and will form part of those documents from the filing date.
Genmab A/S has furnished a Form 6-K for March 2026, primarily to submit its updated Articles of Association as Exhibit 3.1. The filing states that this report will be incorporated by reference into several existing Genmab Form S-8 registration statements and will form part of those documents from the filing date.
Genmab A/S provides an update on its ongoing share buy-back program, which was initiated to repurchase up to 342,130 shares for a maximum of DKK 725 million to honor commitments under its Restricted Stock Unit program.
From February 23 to 27, 2026, Genmab repurchased 18,000, 12,000, 15,000, 20,000 and 20,000 shares on successive trading days, at average prices between DKK 1,825.23 and DKK 1,856.49, for total consideration of DKK 156,630,920 during this period and DKK 271,855,470 accumulated under the program. Following these transactions, Genmab holds 2,763,851 treasury shares, equal to 4.30% of its total share capital and voting rights.
Genmab A/S provides an update on its ongoing share buy-back program, which was initiated to repurchase up to 342,130 shares for a maximum of DKK 725 million to honor commitments under its Restricted Stock Unit program.
From February 23 to 27, 2026, Genmab repurchased 18,000, 12,000, 15,000, 20,000 and 20,000 shares on successive trading days, at average prices between DKK 1,825.23 and DKK 1,856.49, for total consideration of DKK 156,630,920 during this period and DKK 271,855,470 accumulated under the program. Following these transactions, Genmab holds 2,763,851 treasury shares, equal to 4.30% of its total share capital and voting rights.
Genmab A/S filed a Form 6-K as a foreign private issuer for February 2026. The report primarily furnishes an updated corporate document, listing the company’s Articles of Association as Exhibit 3.1. The filing is also incorporated by reference into several existing Genmab Form S-8 registration statements.
Genmab A/S filed a Form 6-K as a foreign private issuer for February 2026. The report primarily furnishes an updated corporate document, listing the company’s Articles of Association as Exhibit 3.1. The filing is also incorporated by reference into several existing Genmab Form S-8 registration statements.
Genmab A/S is making a small share capital increase after employees exercised warrants, issuing 12,313 new shares. The new shares were subscribed for cash at various prices between DKK 1,147.50 and DKK 1,615.00 per share, generating approximately DKK 17.1 million in proceeds for the company.
The new shares equal about 0.02% of Genmab’s existing share capital and carry the same rights as existing ordinary shares, including voting and dividend rights from subscription. After this increase, the total nominal share capital is DKK 64,250,721, corresponding to 64,250,721 shares and votes, and the new shares are expected to be listed on Nasdaq Copenhagen following registration.
Genmab A/S is making a small share capital increase after employees exercised warrants, issuing 12,313 new shares. The new shares were subscribed for cash at various prices between DKK 1,147.50 and DKK 1,615.00 per share, generating approximately DKK 17.1 million in proceeds for the company.
The new shares equal about 0.02% of Genmab’s existing share capital and carry the same rights as existing ordinary shares, including voting and dividend rights from subscription. After this increase, the total nominal share capital is DKK 64,250,721, corresponding to 64,250,721 shares and votes, and the new shares are expected to be listed on Nasdaq Copenhagen following registration.
Genmab A/S provides an update on its recently initiated share buy-back program. The company plans to repurchase up to 342,130 shares with a maximum aggregate value of DKK 725 million to meet obligations under its Restricted Stock Unit program, with completion expected by March 31, 2026.
From February 18 to February 20, 2026, Genmab repurchased 23,000, 25,000 and 15,000 shares, respectively, for a total consideration of DKK 115,224,550. Following these transactions, Genmab holds 2,678,851 treasury shares, representing 4.17% of its total share capital and voting rights.
Genmab A/S provides an update on its recently initiated share buy-back program. The company plans to repurchase up to 342,130 shares with a maximum aggregate value of DKK 725 million to meet obligations under its Restricted Stock Unit program, with completion expected by March 31, 2026.
From February 18 to February 20, 2026, Genmab repurchased 23,000, 25,000 and 15,000 shares, respectively, for a total consideration of DKK 115,224,550. Following these transactions, Genmab holds 2,678,851 treasury shares, representing 4.17% of its total share capital and voting rights.
Genmab A/S filed a Form 6-K reporting insider share trading by its Executive Vice President & Chief Financial Officer, Anthony Pagano. On February 19, 2026, he executed a sale of 1,100 Genmab shares on Nasdaq Copenhagen at an aggregated price of DKK 1,810.10 per share. Individual trades were carried out at prices between DKK 1,810.00 and DKK 1,811.00. The disclosure is made under Article 19 of the EU Market Abuse Regulation and covers trading by a person discharging managerial responsibilities.
Genmab A/S filed a Form 6-K reporting insider share trading by its Executive Vice President & Chief Financial Officer, Anthony Pagano. On February 19, 2026, he executed a sale of 1,100 Genmab shares on Nasdaq Copenhagen at an aggregated price of DKK 1,810.10 per share. Individual trades were carried out at prices between DKK 1,810.00 and DKK 1,811.00. The disclosure is made under Article 19 of the EU Market Abuse Regulation and covers trading by a person discharging managerial responsibilities.